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7RESEARCH Open Access4′-O-methylhonokiol increases levels of
2-arachidonoyl glycerol in mouse brain via
selective inhibition of its COX-2-mediated
oxygenation
Andrea Chicca1*, Maria Salomé Gachet1, Vanessa Petrucci1, Wolfgang Schuehly2, Roch-Philippe Charles1
and Jürg Gertsch1*Abstract
Background and purpose: 4′-O-methylhonokiol (MH) is a natural product showing anti-inflammatory,
anti-osteoclastogenic, and neuroprotective effects. MH was reported to modulate cannabinoid CB2 receptors as an
inverse agonist for cAMP production and an agonist for intracellular [Ca2+]. It was recently shown that MH inhibits
cAMP formation via CB2 receptors. In this study, the exact modulation of MH on CB2 receptor activity was
elucidated and its endocannabinoid substrate-specific inhibition (SSI) of cyclooxygenase-2 (COX-2) and CNS
bioavailability are described for the first time.
Methods: CB2 receptor modulation ([35S]GTPγS, cAMP, and β-arrestin) by MH was measured in hCB2-transfected
CHO-K1 cells and native conditions (HL60 cells and mouse spleen). The COX-2 SSI was investigated in RAW264.7
cells and in Swiss albino mice by targeted metabolomics using LC-MS/MS.
Results: MH is a CB2 receptor agonist and a potent COX-2 SSI. It induced partial agonism in both the [35S]GTPγS
binding and β-arrestin recruitment assays while being a full agonist in the cAMP pathway. MH selectively inhibited
PGE2 glycerol ester formation (over PGE2) in RAW264.7 cells and significantly increased the levels of 2-AG in mouse
brain in a dose-dependent manner (3 to 20 mg kg−1) without affecting other metabolites. After 7 h from intraperitoneal
(i.p.) injection, MH was quantified in significant amounts in the brain (corresponding to 200 to 300 nM).
Conclusions: LC-MS/MS quantification shows that MH is bioavailable to the brain and under condition of inflammation
exerts significant indirect effects on 2-AG levels. The biphenyl scaffold might serve as valuable source of dual CB2 receptor
modulators and COX-2 SSIs as demonstrated by additional MH analogs that show similar effects. The combination of CB2
agonism and COX-2 SSI offers a yet unexplored polypharmacology with expected synergistic effects in neuroinflammatory
diseases, thus providing a rationale for the diverse neuroprotective effects reported for MH in animal models.
Keywords: 4′-O-methylhonokiol, Endocannabinoids, COX-2, CB2 receptor, Polypharmacology, Partial agonist,
Endocannabinoid system, 2-arachidonoyl glycerol, Magnolia grandifloraIntroduction
4′-O-methylhokiol (MH) is the major bioactive constitu-
ent of Magnolia grandiflora L. seed oil and shows pro-
nounced anti-inflammatory, anti-osteoclastogenic, and
neuroprotective effects [1-4]. In mouse models, MH pre-
vents LPS-induced memory loss and β-amyloid (1 to42)
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unless otherwise stated.accumulation [2]. Moreover, MH appears to efficiently
attenuate the development of Alzheimer’s disease in
Tg2576 transgenic mice [3]. The proposed underlying
mechanisms appear to be linked to the inhibition of nu-
clear factor kappa B, the gene expression of inducible ni-
tric oxide synthase and cyclooxygenase-2 (COX-2), as
well as cannabinoid type-2 (CB2) receptors [2,5]. MH
and some derivatives potently inhibit COX-2 with poor
selectivity towards the constitutive isoform COX-1 [6,7].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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related to oxidative stress and MAP kinases, inhibits
moderately acetylcholinesterase activity (see [5] for re-
view), and it also acts as positive allosteric GABAA re-
ceptor ligand [8]. Schuehly et al. [1] for the first time
described the relatively potent and selective CB2 recep-
tor binding of MH and different analogs. MH was shown
to exert an unusual dualistic modulation of CB2 receptor
activity, acting as an inverse agonist at the cAMP pathway
while behaving as an agonist at increasing the intracellular
levels of [Ca2+] [1]. The CB2 receptor inverse agonism on
the cAMP pathway was described as the relevant mechan-
ism associated to anti-osteoclastogenesis effects described
in mouse RAW264.7 cells and primary human mono-
cytes/macrophages. Other authors recently reported that
MH behaves as a CB2 receptor agonist in the cAMP path-
way [9], pointing out discrepancies in receptor assays,
which gave impetus to the present in-depth study on the
CB2 receptor pharmacology of MH. The main degradation
route of endocannabinoids (ECs) is their hydrolysis by
fatty acid amide hydrolase (FAAH) (for anandamide
(AEA)) and monoacylglycerol lipase/α, β-hydrolases
(MAGL/ABHDs) (for 2-arachidonoyl glycerol (2-AG)),
but ECs might undergo additional enzymatic modifica-
tions including oxygenation mediated by COX-2, lipoxy-
genases (LOXs), and cytochrome P450 (CYP450) [10-12].
Several studies emphasized the relevance of COX-2-
mediated oxygenation of ECs in vitro and in vivo under
specific conditions like inflammation and in FAAH knock-
out animals [13-15]. EC oxygenation might be particularly
relevant in inflammation or tissues that constitutively ex-
press the inducible form of COX such as the brain, kidney,
and spinal cord [16-18]. Upon COX-2 activity, AEA and
2-AG are converted into prostaglandin ethanolamides
(prostamides) and prostaglandin glycerol esters (PG-GEs),
respectively [10,11]. Prostamides and PG-GEs exert pro-
inflammatory actions probably by interacting with specific
targets that are different from cannabinoid and classic
prostaglandin receptors. A heterodimeric association be-
tween the wild-type prostaglandin F (FP) receptor and an
alternative splicing variant (Alt4) of such receptors was
identified as molecular target for prostamideF2α [19]. The
hyperalgesic actions of prostamideF2α were then con-
firmed by using selective receptor antagonists which
showed antinociceptive effects in vitro and in vivo [15,20].
The inhibition of prostamide and PG-GEs formation by
COX-2 substrate-specific inhibitors (SSIs) has been re-
ported. Intriguingly, such inhibitors can lead to an increase
of AEA and 2-AG levels without affecting the levels of ara-
chidonic acid (AA) and PGE2 [14,21,22]. Duggan et al. [14]
recently showed that (R)-flurbiprofen acts as COX-2 SSI by
increasing EC levels and by reducing prostamide formation
without affecting AA and PGE2 levels. In addition, the mor-
pholino amide derivative of indomethacin LM-4131showed potent anxiolytic effects in several animal models
by selectively inhibiting EC oxygenation, increasing levels of
AEA and 2-AG in the brain [21]. COX-2 SSI might repre-
sent a promising anti-inflammatory strategy to circumvent
the typical gastrointestinal and cardiovascular aversive ef-
fects of the non-selective COX-2 inhibitors.
Here, we show that MH and some derivatives exert
dual and potentially synergistic actions on the endocan-
nabinoid system (ECS) by acting as central nervous sys-
tem (CNS) penetrating SSIs of COX-2 and as CB2
receptor agonists. We provide detailed analyses on CB2
receptor signaling and COX-2-mediated oxygenation of
ECs by using purified hCOX-2, RAW264.7 cells, and
LPS-challenged mouse brain.
Methods
Materials
[Ethanolamine-1-3H]-anandamide and [1,2,3-3H]-2-ara-
chidonyl glycerol were obtained from American Radiola-
beled Chemicals (St. Louis, MO, USA), while the [3H]
CP-55,940 was obtained from PerkinElmer Life Sciences
(Waltham, MA, USA). AM630, WIN55-212, AEA, 2-
AG, DuP-697, arachidonic acid-d8 (5Z,8Z,11Z,14Z-
eicosatetraenoic-5,6,8,9,11,12,14,15-d8 acid), AEA-d4
(N-(2-hydroxyethyl-1,1,2,2-d4)-5Z,8Z,11Z,14Z-eicosate
traenamide) 2-AG-d5 (5Z,8Z,11Z,14Z-eicosatetraenoic
acid, 2-glyceryl-1,1,2,3,3-d5 ester), LEA-d4 (N-(2-
hydroxyethyl-1,1,2,2-d4)-9Z,12Z-octadecadienamide);
OEA-d4 (N-(2-hydroxyethyl-1,1,2,2-d4)-9Z-octadece-
namide), PEA-d5 (N-(2-hydroxyethyl)-hexadecana-
mide-15,15,16,16,16-d5); PGE2-d4 (9-oxo-11α,15S-
dihydroxy-prosta-5Z,13E-dien-1-oic-3,3,4,4-d4 acid);
and PGE2-1-glyceryl ester-d5 (9-oxo-11α,15S-dihy-
droxy-prosta-5Z,13E-dien-1-oic acid,1-glyceryl ester-
d5) were obtained from Cayman Chemicals Europe
(Ann Arbor, MI, USA). MH-d6 (2-(4-methoxy-3-prop-2-
enylphenyl (d))-4-prop-2-enylphenol (d)). The structures
of the MH derivatives were previously published in
Schühly et al. [7] and Schuehly et al. [1]. The procedure of
isolation and purification of MH and the synthesis of its
derivatives was previously reported in [1,7]. All tubes used
for assays (plastic and glass) were silanized.
Animals
All study involving animals are reported in accordance
with the Swiss Federal guidelines. Female RjOrl: SWISS
(60) 7 to 8 weeks old, provided by Janvier Labs (St
Berthevin, France), were used for these experiments. The
mice were housed in groups of five per cage in a selected
pathogen-free unit under controlled 12-h light/12-h dark
cycle, ambient temperature 21°C ± 1°C humidity 40% to
50% with free access to standard rodent chow and water.
The mice were acclimatized to the Animal House for at
least 3 days before the experiment.
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receptors
Receptor binding experiments were performed with
membrane preparations as previously reported [23].
Briefly, clean membranes expressing hCB1 or hCB2 were
resuspended in binding buffer (50 mM Tris-HCl, 2.5
mM EDTA, 5 mM MgCl2, 0.5 mg mL
−1 fatty acid-free
bovine serum albumin (BSA), pH 7.4) and incubated
with vehicle or compounds and 0.5 nM of [3H]
CP55,940 for 2 h at 30°C. Non-specific binding was de-
termined in the presence of 10 μM of WIN55,512. After
incubation, membranes were filtered through a pre-
soaked 96-well microplate bonded with GF/B filters
under vacuum and washed twelve times with 150 μL of
ice-cold binding buffer. The radioactivity was measured
and the results expressed as [3H] CP55,940 binding.
[35S]GTPyS assay
Assays were performed as previously described [24].
Briefly, 5 μg of clean membranes expressing hCB2 were
diluted in binding buffer (50 mM Tris-HCl, 3 mM
MgCl2, 0.2 mM EGTA, and 100 mM NaCl at pH 7.4
plus 0.5% fatty acid-free BSA) in the presence of 10 μM of
GDP and 0.1 nM of [35S]GTPγS. The mixture was kept on
ice until the binding reaction was started by adding the ve-
hicle or compounds. Non-specific binding was measured
in the presence of 10 μM of GTPγS. The tubes were incu-
bated at 30°C for 90 min. The reaction was stopped by
rapid filtration through a 96-well microplate bonded with
GF/B filters previously pre-soaked with washing buffer (50
mM of Tris-HCl pH 7.4 plus 0.1% fatty acid-free BSA).
The filters were washed six times with 180 μL of washing
buffer under vacuum. Experiments were performed in the
presence and after removal of constitutive activity of CB2
receptors. In the latter, membranes were obtained from
cells treated overnight with 10 μM of AM630 to shift the
vast majority of the receptor population in the inactive
state. After the incubation, cells were washed six times
with 10 mL of culture medium for 10 min each. Finally,
cells were detached and membranes prepared and used to
perform [35S]GTPγS binding assays. Membrane obtained
from mock-transfected CHO cells were used as negative
control. Membranes derived from mouse spleen (20 μg)
and human promyelocytic leukemia HL60 cells (40 μg)
were used as sources of CB2 receptors expressed in native
conditions. In order to reduce the basal [35S]GTPγS bind-
ing, the experiments were performed after 30-min pre-
treatment with adenosine deaminase (5 units mL−1). The
radioactivity was measured, and the results were expressed
as [35S]GTPγS binding.
cAMP assay
cAMP assays were performed in CHO-hCB2 stably
transfected with the pGloSensorTM 22-F plasmid(Promega, Madison, WI, USA) as previously described
[22]. Briefly, cells were seeded in 96-well plate and kept
in an equilibration medium (GloSensor™ cAMP reagent
diluted in 5% of a CO2-independent medium plus 10%
FBS) for 2 h at RT in the dark. Compounds or vehicle
were diluted in an assay medium containing 1 μM of
forskolin and 250 μM of 3-isobutyl-1-methylxanthine
(IBMX). Chemiluminescence was recorded after 20 min.
Non-specific signal was determined in cells with only
IBMX. Experiments were performed in the presence and
after removal of the constitutive activity of the receptors
following the same procedure described above. Results
were normalized by subtracting the residual cAMP pro-
duction and expressed amount of cAMP formed.
β-arrestin assay
The PathHunter® β-arrestin cells (CHO-K1-HOMSA-
CNR2) were gently donated by DiscoverX (via Hoffman
La-Roche Ltd, Basel, Switzerland) and cultured in an F-
12 medium containing 10% FBS, 200 μg mL−1 hygromy-
cin and 800 μg mL−1 geneticin. For the experiments, 2 ×
104 cells were seeded in 96-well plate and left overnight
in the incubator. The day after, vehicle or compounds
were diluted in 40 μL of a CO2-independent medium
plus 10% FBS. The mixture was added to the cells and in-
cubated for 90 min at 37°C. Chemiluminescence was de-
tected using the PathHunter® detection system (DiscoveRx
Corporation, Fremont, CA, USA) according to the in-
struction protocol. Background levels were subtracted and
the results expressed as β-arrestin recruitment.
COX-2 inhibition assay in vitro
The experiments were performed as previously de-
scribed [22]. Briefly, the inhibition of recombinant
hCOX-2 was assessed using a COX fluorescent inhibitor
screening assay kit from Cayman Chemicals Europe.
Tested compounds or vehicle were pre-incubated with
COX-FIS assay buffer (Tris-HCl 100 mM, pH 8), 1 μM
of COX-FIS heme hCOX-2 FIS assay agent, and 30 μM
of ADHP (10-acetyl-3,7-dihydroxyphenoxazine) fluoro-
metric substrate for 15 min at RT. The reaction was
started by adding arachidonic acid, AEA, or 2-AG (10
μM). Fluorescence intensity was measured (535/580 nm)
after 5 min of incubation. The results were expressed as
hCOX-2 activity.
LC-MS/MS quantification of ECs and PGs in RAW264.7 cells
In case of experiments with homogenates, cells were
seeded in T75-cm2 flask and stimulated with LPS (1 μg
mL−1) for 12 h at 37°C. After incubation, cells were ho-
mogenized in assay buffer (Tris-HCl 10 mM, pH 8) and
900 μg of total protein were used to perform the COX-2
assay. When using intact cells, 0.5 × 106 cells were
seeded in a 24-well plate and challenged with LPS (1 μg
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replaced by a medium containing vehicle or compounds.
After 30 min of incubation at 37°C, 2-AG (10 μM) was
added and plates were incubated for an additional 30
min at 37°C. Further experiments were carried out with-
out adding 2-AG but stimulating its cellular biosyn-
thesis. In this setting, RAW264.7 cells were treated for 8
h with LPS (1 μg mL−1), ATP (1 mM), and thapsigargin
(2 μM) in the presence of vehicle or compounds. In both
experimental conditions, after the incubation, cells were
detached, transferred into a chloroform:methanol mix-
ture (2:1) containing the internal standards (ISs), and
then, phosphate buffered saline (PBS) was added to the
final ratio of 6:3:1.5 (chloroform:methanol:PBS). The
suspension was vortexed, sonicated, and centrifuged for
5 min at 800 g at 4°C. The organic phase was recovered
and dried under nitrogen. The quantification of AA, 2-
AG, PGE2, and PGE2GE was performed using LC-MS/
MS. The multiple reaction monitoring (MRM) parameters
(precursor ion/product ion, declustering potential, colli-
sion energy) used in the survey and the respective IS are
detailed in Gachet et al. [25] for all analytes except for:
MH (Q): 279/264 m/z, −70 eV, −23 eV and (q): 279/248
m/z, −70 eV, −40 eV; MH-d6: 285/279 m/z, −82 eV, −24
eV; PGE2GE (Q): 444/409 m/z, 40 eV, 13 eV and (q): 444/
373 m/z, 40 eV, 19 eV; and PGE2GE-d5: 449/396 m/z, 43
eV, 17 eV. The quantification was based on the area ratio
of analytical standard/IS.
LC-MS/MS quantification of ECs and PGs in vivo
Swiss albino mice (females, 8 weeks old) were injected
intraperitoneally (i.p.) with vehicle or MH at different
doses (3, 10, and 20 mg kg−1). Female mice were used
for ethical reasons because they were less susceptible for
neuroinflammatory damage in this model. After 1 h, the
animals (6 to 14 animals per group) were injected i.p.
with LPS (2.5 mg kg−1) and kept in the dark for an add-
itional 6 h. After anesthetization, mice were perfused
with PBS and the brains were collected. Lipid extraction
was performed as recently described (Gachet et al. [25]).
In brief, half brain was homogenized on a BeadBeater
(Mini-BeadBeater-24, BioSpec, Bartlesville, OK USA)
using Chrome-Steel Beats (2.3 mm dia., BioSpec) in the
presence of ice-cold chloroform:methanol (2:1) for 1
min (3,450 strokes min−1) at 4°C. Homogenates were
added with PBS (containing ISs) to the final ratio of
6:3:1.5 (chloroform:methanol:PBS). The suspension was
vortexed, sonicated, and centrifuged for 5 min at 800 g
at 4°C. The organic phase was recovered and dried
under nitrogen. Subsequently, the samples were recon-
stituted in ethanol and after the addition of water and
pH adjustment (pH = 3), an aliquot was extracted using
C-18Sep-Pak cartridge (Waters AG, Zug, Switzerland).
Cartridges were washed with 10% ethanol and elutedwith acetonitrile (ACN)/ethyl acetate (1:1). The eluates
were collected and evaporated to dryness under nitrogen.
The samples were reconstituted in ACN, centrifuged for 5
min at 16,100 g at 4°C, and measured by LC-MS/MS in
negative and positive modes. The quantification was based
on the area ratio of analytical standard/IS.
[3H]AEA and [3H]2-AG hydrolysis assay
The experiments were performed as previously de-
scribed [23]. Briefly, vehicle or compounds were pre-
incubated for 30 min at 37°C with 200 μg of pig brain
homogenate for FAAH and MAGL and 100 μg of BV-2
cell homogenate for ABHDs in assay buffer (10 mM
Tris-HCl, 1 mM EDTA, pH 7.6 plus 0.1% fatty acid-free
BSA). To measure FAAH activity, a mixture of AEA/
[3H] AEA was added to the homogenate (final concen-
tration of 1 μM) and incubated for 15 min at 37°C. After
incubation, tubes were added with chloroform:methanol
(1:1), vortexed, and centrifuged at 10,000 rpm for 10
min at 4°C. To measure MAGL/ABHDs activity, AEA
and [3H]AEA were replaced by 2-oleoylglycerol (2-OG)
and [3H]2-OG, respectively. The radioactivity associated
to the [3H]ethanolamine (or [3H]glycerol) formation was
measured in the aqueous phase. The results were
expressed as enzymatic activity.
[3H]AEA uptake into U937 cells
The experiments were performed as previously de-
scribed [23]. Briefly, 106 of U937 cells were suspended in
0.5 mL of PBS and pre-incubated with vehicle or com-
pounds for 30 min at 37°C. Successively, cells were
added with a mixture of AEA/[3H]AEA (final concentra-
tion of 100 nM) and incubated for 5 min at 37°C. The
uptake process was stopped by rapid centrifugation at
800 g for 5 min at 4°C. The supernatant was discarded
and the pellet washed with ice-cold PBS plus 1% of fatty
acid-free BSA. Cell pellets were resuspended in PBS and
extracted with chloroform:methanol (1:1). The organic
phase was collected and the radioactivity measured. The
results were expressed as [3H]AEA uptake. In case of
U937 cell-derived macrophages, U937 cells were treated
for 48 h with 2 ng mL−1 of phorbol 12-myristate 13-
acetate (PMA) and the uptake experiments were per-
formed as described above.
Data analysis
Data were collected from at least three independent ex-
periments each performed in triplicate. Results are
expressed as mean values and standard deviation (SD).
The [35S]GTPγS assays performed using CHO-hCB2
membranes were repeated five times, and the error was
expressed as standard error of the mean (SEM). The
statistical significance difference among groups was de-
termined by Student’s t test (paired, two-tailed t test) or
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Statistical differences between treated and control
groups were considered as significant if P ≤ 0.05. Graph-
Pad 5.0 software was used to fit the concentration-
dependent curves and for the statistical analysis.
Results
First, we confirmed that MH (Figure 1) selectively binds
to CB2 receptors with a Ki value of 188.5 (131.7 to
269.4) nM over 2.4 (1.9 to 2.9) μM for CB1 receptors
(Table 1). MH induced a concentration-dependent in-
crease of [35S]GTPγS binding with an EC50 value of
285.7 (125.6 to 647.2) nM and a maximal binding of
185.7% (167.1 to 204.3) (Figure 2A). In the same assay,
the positive control 2-AG-induced [35S]GTPγS binding
with an EC50 value of 74.0 (28.4 to 192.9) nM, reaching
252.8% (210.2 to 295.4) of maximal response. Statistical
analyses confirmed that MH induced a lower maximal
G-protein recruitment compared to the endogenous full
agonist 2-AG, thus suggesting partial agonism. Partial
agonists are versatile ligands which can behave as ago-
nists or antagonists depending on the conditions [26]. In
Figure 2B, the incubation of fixed concentrations of MH
with increasing concentrations of 2-AG exemplifies these
opposite pharmacological behaviors. While MH induced
G-protein recruitment at inactive 2-AG concentrations, it
reduced the effects induced by high concentrations of the
full agonist. We also investigated the behavior of MH
using human promyelocytic leukemia HL60 cells [27] and
mouse spleen [28] which both endogenously express CB2
receptors. As reported in Figure 2C,D, 2-AG, CP55,940,
and MH behaved as agonists by increasing the [35S]GTPγS
binding compared to vehicle, while SR144528 and AM630OH
O
27a4’-O -methylhonokiol (MH)
OH
O
OH
HO
32
OH
O
34a
Figure 1 Chemical structures of 4′-O-methylhonokiol (-4′-methoxy-5,3′-
di-(2-propenyl)-biphenyl-2-ol), 27a (2-methoxy-5,3′-di-(2-propenyl)-
biphenyl-4′-ol), 32 (5,5′-di-sec-butyl- biphenyl-2,2′-diol) and 34a
(2-butyloxy-5,3′-di-(2-propenyl)- biphenyl-4′-ol).reduced G-protein recruitment, thus behaving as inverse
agonists. In agreement with the results obtained in CHO-
hCB2 membranes, MH induced a sub-maximal binding of
[35S]GTPγS compared with the full agonists CP55,940 and
2-AG, in both HL60- and spleen-derived membranes, thus
confirming its partial agonist behavior. In addition, we also
tested 2-AG, CP55,940, and MH effects using membranes
derived from mock-transfected CHO cells. All ligands
showed no change of the basal level of [35S]GTPγS bind-
ing (Additional file 1: Figure S1). Altogether, these data in-
dicate that MH behaves as an agonist at CB2 receptors in
both overexpressing and native conditions. We next char-
acterized the effects of MH on the CB2 receptor-mediated
inhibition of forskolin-induced cAMP production. As
shown in Figure 2E, increasing concentrations of MH
inhibited cAMP formation with an IC50 value of 674 (481
to 944) nM. In this assay, in contrast to previous results
[1], MH behaved as a full agonist producing the same
maximal inhibition as the full agonist 2-AG (data not
shown). CB2 receptors are known to possess a high intrin-
sic constitutive activity. Therefore, compounds that act as
‘protean agonists’ can behave differently depending on the
proportion of constitutively activated receptors. ‘Protean
agonists’ bind to the receptor and stabilize an active con-
formation that is capable of initiating signal where there is
none (inactive state of the receptor), but they trigger an
active state of the receptor that is less efficacious than the
naturally occurring, spontaneously formed constitutive ac-
tive state [29]. Thus, ‘protean agonists’ can behave as an
agonist or inverse agonist depending on the active state of
the receptor. This phenomenon has been accurately inves-
tigated over the past few years, and it was found that by
pre-treating CB2 receptors overnight with the inverse
agonist AM630, most of the receptors shift towards the in-
active state, thus abolishing the constitutive activity [30].
For example, an inverse agonist becomes a silent antagon-
ist [30] and a protean agonist can switch from an inverse
agonist to an agonist or antagonist [30,31]. We have vali-
dated our assay system by showing that after removing the
constitutive activity, AM630 and SR144528 switched from
an inverse agonist to a silent antagonist, while CP55,940
did not change its behavior (Additional file 1: Figure S2)
in agreement with the literature [30,32]. As shown in
Figure 2E, MH acted as a full agonist in both conditions,
suggesting that in our assay, the level of constitutive activ-
ity of CB2 receptors did not qualitatively affect the
pharmacological behavior of MH. We also investigated the
effect of MH on β-arrestin recruitment. In Figure 2F, it is
clearly shown that similarly to [35S]GTPγS results, the
compound induced a sub-maximal effect compared to
CP55,940, therefore behaving as a partial agonist. MH has
been shown to inhibit the COX-2-mediated AA oxygen-
ation [7]. However, COX-2 is responsible also for the oxy-
genation of AEA and 2-AG leading to the formation of
Table 1 Summary of the pharmacological effects exerted by MH, 27a, 32, and 34a
IC50 or Ki values (mean value ± SD, μM)
hCOX-2 RAW264.7 Intact cells CHO membranes CHO cells Pig brain homog. BV-2 homog. U937 cells
AA 2-AG AA 2-AG hCB1 hCB2 hCB2 [
35S] GTPγS hCB2 cAMP FAAH MAGL ABHDs AEA uptake
MH 0.58 ± 0.08 **0.15 ± 0.09 1.56 ± 0.12 **0.28 ± 0.09 2.4 ± 0.6 0.19 ± 0.12 0.20 ± 0.10 0.67 ± 0.07 >10 >10 >10 6.5 ± 1.2
27a 1.21 ± 0.08 **0.42 ± 0.09 0.98 ± 0.08 **0.28 ± 0.11 0.79 ± 0.10 0.11 ± 0.09 0.18 ± 0.09 0.71 ± 0.09 >10 >10 >10 >10
32 10.2 ± 0.12 **0.63 ± 0.05 2.8 ± 0.22 **0.21 ± 0.14 >10 >10 n.d. n.d. >10 >10 >10 6.3 ± 1.6
34a 4.31 ± 0.10 *1.29 ± 0.07 >30 **1.57 ± 0.13 1.12 ± 0.15 0.35 ± 0.11 1.82 ± 0.14 1.52 ± 0.13 >10 >10 >10 >10
DuP-697 0.061 ± 0.005 0.07 ± 0.01 0.004 ± 0.004 0.005 ± 0.006 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
The data are expressed as mean ± SD of at least three independent experiments each performed in triplicates. Binding affinity to CB1 and CB2 receptors is expressed as Ki value while modulation of CB2 receptor
activation (cAMP and [35S] GTPγS) and inhibition of enzyme activity and AEA uptake are expressed as IC50 value. *P < 0.05; **P < 0.01 PGE2-GE vs. PGE2. n.d.: not determined P < 0.05; **P < 0.01 PGE2-GE vs. PGE2. Items
in bold are compound abbreviations.
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Figure 2 Modulation of CB2 receptor activity by MH. (A) [
35S]GTPγS binding assay was performed in stably hCB2 receptor overexpressing CHO-K1
membranes, in the presence of different concentrations of MH and 2-AG alone or (B) in combination. The same experiments were performed in
endogenously CB2 expressing (C) HL60 cells and (D) mouse spleen membranes. (E) Inhibition of forskolin-induced cAMP formation by MH in
CHO-hCB2 cells transfected with pGloSensorTM 22-F plasmid. The experiments were performed in the presence (circles) and in the absence
(triangles) of constitutive activity. (F) β-arrestin recruitment induced by increasing concentrations of MH, CP55,940, and AM630, measured in
PathHunter® β-arrestin cells (CHO-K1-HOMSA-CNR2). **P < 0.01 MH vs. 2-AG (Figure 2A); **P < 0.01 MH (1 μM) plus 2-AG vs. 2-AG, ++P < 0.01,
+P < 0.05 MH (0.3 μM) plus 2-AG vs. 2-AG (Figure 2B). *P < 0.05 MH vs. 2-AG and CP55,940 (Figures 2C, D).**P < 0.01 MH vs. CP55,940 (Figure 2F).
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fore, we next studied whether MH selectively inhibits the
COX-2-mediated oxygenation of ECs. In Figure 3A, the
concentration-dependent inhibition of purified hCOX-2 is
shown using 10 μM of AEA, 2-AG, and AA as substrates.
Noteworthy, MH inhibited the oxygenation of ECs with
IC50 values of 158 (123 to 204) nM and 156 (129 to 189)
nM for AEA and 2-AG, respectively, while it blocked AA
oxygenation with an IC50 value of 588 (499 to 693) nM
(Table 1). We then confirmed the apparent SSI of COX-2
in LPS-stimulated RAW264.7 cells by using cell homoge-
nates and intact cells. We quantified the amount of PGE2
and PGE2-GE formation by LC-MS/MS analysis after in-
cubation for 30 min with 10 μM of 2-AG. As shown in
Figure 3B,C, MH inhibited PGE2-GE formation with ahigher potency (IC50 value: 301 (257 to 490) nM) com-
pared to PGE2 (IC50 value: 1.21 (0.792 to 1.81) μM) in
both systems. The mass chromatograms of PGE2 and
PGE2-GE formed upon incubation of LPS-stimulated
RAW264.7 cell homogenates as well as from intact
cells incubated with 2-AG are shown in Figure 4. The
LC-MS/MS method was validated by measuring the non-
selective COX-2 inhibitor DuP-697 which showed the
same potency in inhibiting the oxygenation of ECs and
AA (Figure 3A,B,C,D). RAW264.7 cells can be stimulated
to produce significant levels of 2-AG by raising intracellu-
lar levels of [Ca2+]. Cells were stimulated for 8 h with LPS,
ATP, and thapsigargin in the presence of vehicle or differ-
ent concentrations of MH. Figure 5A, B shows the
concentration-dependent inhibition of PGE2 and PGE2-
CB
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Figure 3 Dose-dependent COX-2 inhibition induced by MH in different biological matrices. (A) MH-mediated inhibition of hCOX-2 using 10 μM
of AA (black), AEA (blue), and 2-AG (red) as substrates. MH-mediated inhibition of PGE2 and PGE2-GE formation in (B) RAW264.7 cell homogenate
and (C) intact cells after 12 h of incubation with LPS (1 mg mL−1). Homogenates and intact cells were incubated for 30 min with 10 μM of 2-AG
after the pre-treatment (30 min) with different concentrations of MH or vehicle. *P < 0.05, **P < 0.01 PGE2 vs. PGE2-GE.
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Figure 4 MS chromatograms of PGE2 and PGE2-GE measured in different biological matrices. Quantification of PGE2 and PGE2-GE formation
measured after incubation of (A) RAW264.7 cell homogenate and (B) intact cells with 10 μM of AA or 2-AG in the presence of different
concentrations of MH or vehicle. Homogenates and cells were treated for 12 h with LPS (1 mg mL−1) followed by 30-min incubation with
10 μM of 2-AG after the pre-treatment (30 min) with different concentrations of MH or vehicle.
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trations (10 to 30 nM), MH led to 20% to 25% inhibition
of 2-AG oxygenation while AA oxygenation was not af-
fected. At high concentrations (100 to 300 nM), MH
inhibited the formation of both prostaglandin types but
with more pronounced effects on PGE2-GE. At 1 μM, MH
almost fully inhibited COX-2-mediated oxygenation of
AA and 2-AG lacking the substrate specificity (Figure 5C).
Since the absolute amount of PGE2 formed was about
100-times higher than PGE2-GE, we wanted to exclude a
potential bias in the sensitivity of the system due to differ-
ent amounts of the initial substrates (AA and 2-AG).
Therefore, we tested the effects of DuP-697, and the re-
sults confirmed that this non-selective inhibitor potently
blocked the formation of PGE2 and PGE2-GE with the
same potency (Additional file 1: Figure S3E). To assess the
relevance of COX-2 SSI in vivo, we evaluated the effects of
MH in LPS-challenged Swiss albino mice. Animals were
injected intraperitoneally (i.p.) with vehicle or different
concentrations of MH and after 1 h, challenged for 6 h
with LPS. Brain levels of AEA, 2-AG, AA, and PGE2,
expressed as nmol (or pmol) mg−1 of tissue are shown in
Figure 6A,B,C,D. Upon LPS injection, the amount of AA,
2-AG, and AEA did not significantly change, while PGE2
and corticosterone strongly increased (Figure 6E), asexpected, and in agreement with the literature [34,35].
MH treatment did not affect the amount of AA and cor-
ticosterone at any concentration, while it slightly reduced
the levels of PGE2 only at 20 mg kg
−1. MH did not sig-
nificantly affect AEA levels, while significantly increas-
ing the amount of free 2-AG at 10 and 20 mg kg−1, with
a tendency of increase also at the lowest dose tested (3
mg kg−1). Since 2-AG levels are about 500 to 1,000
times higher than AEA levels in Swiss albino mice, and
assuming that both ECs are equipotent substrates for
COX-2, it is not unexpected to see this more pro-
nounced effect (doubling the amount) of a SSI COX-2
inhibitor on 2-AG levels. PGE2-EA and PGE2-GE were
below the limit of detection. Moreover, NA-GABA (N-
arachidonoyl GABA) and other N-acylethanolamines
were not significantly affected by MH (Additional file 1:
Figure S4). These findings suggest that MH maintained
the ability to specifically inhibit COX-2-mediated EC
oxygenation in vivo without affecting the oxygenation
of AA. Several publications have recently demonstrated
in vitro and in vivo beneficial effects of MH in neurode-
generative disease models [2,4,36]. Nonetheless, the
penetration of the compound across the blood-brain
barrier has never been investigated. We therefore estab-
lished an LC-MS/MS method to quantify MH in the
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Figure 6 LC-MS/MS quantification of different analytes in mouse brain. (A) AEA, (B) 2-AG, (C) AA, (D) PGE2, and (E) corticosterone were quantified
in the brains from mice (6 to 14 animals per group) challenged for 6 h with LPS (i.p., 2.5 mg kg−1, or saline), after 1 h of pre-treatment with MH
(i.p., 3, 10, and 20 mg kg−1) or vehicle. (F) MH quantification in the brain of LPS-challenged mice. *P < 0.05, **P < 0.01 treated vs. not-treated
animals (Figure 6A-E) and *P < 0.05 MH 10 mg kg−1 vs. 20 mg kg−1 (Figure 6F).
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10, and 20 mg kg−1, the brain contains 120.1 (93.6 to
147.5), 239.8 (121.1 to 342.3), and 350.2 (248.1 to 426.9)
pmol g−1 of MH, respectively (Figure 6F). These results
correlate with the significant increase of EC levels in-
duced by 10 and 20 mg kg−1 of MH, while only showing
a tendency at 3 mg kg−1. An increase of 2-AG levels can
also be achieved by inhibiting its hydrolysis. Therefore,
we tested the effects of MH on all the major EC hydro-
lytic enzymes (FAAH, MAGL, ABHDs) confirming that
it does neither affect AEA nor 2-AG hydrolysis (Table 1),
while the positive controls URB597, JZL184, and
WWL70/tetrahydrolipstatin (for FAAH, MAGL, and
ABHDs, respectively) inhibited EC hydrolysis as in
agreement with the literature (data not shown) [22].
The trafficking of ECs across plasma membranes is
likely regulated by a putative EC membrane transporter
(EMT), and several inhibitors prevent intracellular ac-
cumulation of AEA and 2-AG [37]. MH only weakly
inhibited the cellular accumulation of [3H]AEA in U937
cells with an IC50 value of 6.5 (4.7 to 9) μM (Table 1). A
similar potency (EC50 value of 2.7 (1.1 to 6.5) μM) was ob-
served using U937 cells differentiated into macrophageswhich lack the [3H]ethanolamine incorporation into phos-
pholipids (as shown previously [37]), therefore ruling out
potential effects on other targets indirectly related to the
process of [3H]AEA uptake (Additional file 1: Figure S5).
In the same system, the positive control UCM707 inhib-
ited [3H]AEA uptake with an IC50 value of 1.6 (0.8 to 2.5)
μM and 2.4 (1.2 to 3.6) μM in U937 cells and U937 cells
differentiated into macrophages, respectively, in agree-
ment with previous reports [23,37]. Thus, with nanomolar
brain concentrations of MH, the inhibition of EC traffick-
ing is unlikely to contribute to raising 2-AG levels in vivo.
We tested a library of 40 MH, magnolol, and honokiol
analogs for COX-2 SSI previously described [1,7]. Com-
pounds which showed >50% inhibition of 2-AG oxygen-
ation at 2 μM were selected for further investigations.
As shown in Additional file 1: Figure S6A, B, from the
whole library, only three molecules (27a, 32, and 34a,
see Figure 1 for chemical structures) showed a stronger,
selective inhibition of 2-AG oxygenation over AA. We
characterized the effects of these three compounds in
purified hCOX-2, RAW264.7 cell homogenates, and in-
tact cells similarly to MH. As shown in Figure 7, all
compounds selectively inhibited 2-AG oxygenation with
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Figure 7 COX-2 inhibition by biphenyl neolignans in different biological matrices. (A-D) 27a, (E-H) 32, and (I-L) 34a inhibition of 2-AG, AEA, and
AA oxygenation in hCOX-2 (A, E, I), RAW264.7 cell homogenates (B, F, J), and intact cells (C, G, K) incubated with 10 μM of substrate (2-AG, AEA,
or AA depending on the assay). (D, H, L) Inhibition of PGE2 and PGE2-GE formation in RAW264.7 cells upon LPS (1 mg mL
−1) ATP (1 mM) and
thapsigargin (2 μM) treatment without externally adding 2-AG. *P < 0.05, **P < 0.01 PGE2-GE vs. PGE2.
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cells (34a). Compounds 32 and 34a showed the greatest
selectivity for 2-AG oxygenation (10/15-fold more po-
tent than AA oxygenation (Table 1)). At 10 μM, 32 did
not show any relevant binding at both CB receptor sub-
types, while 27a and 34a showed selective CB2 binding
(Table 1). Next, we characterized the functional effects
of both ligands by assessing G-protein and β-arrestin re-
cruitment and cAMP formation. Compound 27a, which
was previously reported to be an inverse agonist [1], in
our settings like MH behaved as a partial agonist in the
[35S]GTPγS assay (Figure 8A), exhibiting full agonism
at inhibiting the forskolin-induced cAMP production
(Figure 8B) and sub-maximal recruitment of β-arrestin
(Figure 8C). However, compound 34a reduced [35S]GTPγS
binding and increased cAMP formation, thus behaving as
an inverse agonist (Figure 8A, B). Interestingly, when theconstitutive activity was removed, 34a behaved as an agon-
ist by increasing the [35S]GTPγS binding and inhibiting the
forskolin-induced cAMP formation (Figure 8A, B). This
dual effect is a typical feature of ‘protean agonists’ [29].
In the β-arrestin assay, 34a did not show any significant
effect despite a tendency to weakly reduce β-arrestin re-
cruitment by 10% (Figure 8C). The IC50 values of 27a
and 34a for the [35S]GTPγS assay and cAMP assay are
reported in Table 1. All three compounds (27a, 32, and
34a) did not show any significant interaction with other
components of the ECS apart from the magnolol deriva-
tive (32) which weakly inhibited the [3H]AEA uptake
(IC50 value of 6.3 (3.2 to 9.2) μM) similarly to MH.
Similarly to MH, also compound 32 showed the same
potency of inhibiting [3H]AEA uptake in U937 cells and
U937-derived macrophages (EC50 value of 2.4 (0.9 to
6.1 μM) (Additional file 1: Figure S5).
-9 -8 -7 -6 -5
0
50
100
150
200
250
with const. act.
w/o const. act.
Log [34a] (M)
cA
M
P
 p
ro
du
ct
io
n 
(%
 o
f I
B
M
X
/F
S
K
)
-10 -9 -8 -7 -6 -5
0
20
40
60
80
100
120
with const. act
w/o const. act
Log [27a] (M)
cA
M
P
 p
ro
d
uc
tio
n
 (
%
 o
f I
B
M
X
/F
S
K
)
-11-10 -9 -8 -7 -6 -5
50
100
150
200
250
300
27a2-AG
*****
Log [compound] (M)
[3
5 S
]G
T
P
γ S
 b
ou
nd
 (
%
 o
f v
eh
ic
le
)
-11-10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
120
140
34a
AM630
Log [compound] (M)
[3
5 S
]G
T
P
γ S
 b
ou
nd
 (
%
 o
f 
ve
hi
cl
e)
-11-10-9 -8 -7 -6 -5 -4
50
100
150
200
250
27a
34a
AM630
CP55,940
**
**
**
******
Log [compound] (M)
β -
A
rr
es
tin
 r
ec
ru
itm
en
t
(%
 o
f 
ve
h
ic
le
 c
o
n
tr
o
l)
A
B
C
Figure 8 Modulation of CB2 receptor activity by 27a and 34a. (A) [
35S]GTPγS binding assay performed in CHO-K1 membranes containing hCB2
receptors, in the presence of different concentrations of 27a and 34a. The CB2 inverse agonist AM630 is reported as positive control (red line).
Experiments were performed in the presence (dotted line) and in the absence (solid line) of constitutive activity of the receptors. (B) Inhibition of
forskolin-induced cAMP formation by 27a and 34a in CHO-hCB2 cells transfected with pGloSensorTM 22-F plasmid. The experiments were
performed in the presence (dotted line) and in the absence (solid line) of constitutive activity. (C) β-arrestin recruitment induced by increasing
concentrations of 27a and 34a, measured in PathHunter® β-arrestin cells (CHO-K1-HOMSA-CNR2). *P < 0.05, **P < 0.01 27a vs. 2-AG (Figure 8A);
*P < 0.05, **P < 0.01 27a and 34a vs. CP55, 940 (Figure 8C).
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MH is a selective and potent CB2 ligand which was ori-
ginally described as a full agonist at intracellular [Ca2+]
and an inverse agonist at Gi/o recruitment by Schuehly
et al. [1]. Recently, another group reported the agonist
behavior of MH also on the cAMP pathway [9]. In the
present study, using different standardized receptor sig-
naling assays, we found that MH behaves as a partial
agonist in the [35S]GTPγS binding in overexpressing sys-
tems and native conditions and in β-arrestin recruitment
assays, while acting as a full agonist at the cAMP path-
way. Similar differential actions between the G-protein
recruitment and adenylate cyclase modulation have been
reported for other GPCRs like. For example, morphine
and fentanyl induced total inhibition of cAMP formation
upon binding to μ-opioid receptors, while only showing
75% to 80% of maximal G-protein activation compared
to the full agonist etorphine [38]. The [35S]GTPγS bind-
ing assay monitors the first step of G-protein activation
but does not provide further information about the
downstream signaling pathways which can be differently
affected by different ligands. Thus, GPCRs may be coupled
prevalently with one type of G-protein, but depending onthe system (native vs. overexpressing) and the type of tis-
sue, the same receptor might activate different types of G-
protein [28,30]. For example, CB1 receptors are usually
coupled to Gi/o but under certain conditions can also re-
cruit stimulatory G-protein [39,40], or can induce pertus-
sis toxin-independent increase of intracellular [Ca2+] via
Gq/11 recruitment [41]. It has been reported that CB1 re-
ceptors expressed in HEK-293 cells can transduce the
signal via Gi/o when activated by CP55,940, 2-AG, or Δ9-
THC, while WIN55,212-2 induced a CB1-mediated Gq/11
signaling [41]. This suggests that different ligands can trig-
ger distinct active conformations of the receptor which, in
turn, can recruit different types of G-proteins. In addition,
ligands can also alternatively transduce the signal either
via Gα- or Gβγ-subunit as it was recently proposed for
Δ9-THC and 2-AG which modulate COX-2 expression in
opposite ways by activating CB1 receptors in neurons [42].
The level of complexity is also raised by G-protein-
independent signaling pathways such as β-arrestin, whose
receptor-mediated recruitment can modulate several
downstream effectors (e.g., MAPK, ERK1/2, PI3K) besides
its role in the desensitization and internalization process
(see [43] for review). The introduction of the ‘biased
Chicca et al. Journal of Neuroinflammation  (2015) 12:89 Page 13 of 16agonism’ (or functional selectivity) concept triggered a
shift from the classic definition of agonism, antagonism,
and inverse agonism towards the characterization of li-
gands which can preferentially activate only one (or few)
signaling pathways [44]. It is well established that CB2 re-
ceptors possess high levels of constitutive activity and a
high degree of trafficking from intracellular pools to the
membrane surface and vice versa [45]. As reported by
Schuehly et al. [1], MH and 27a inhibit osteoclastogenesis
by acting as inverse agonists on the CB2-mediated cAMP
pathway. We now show that both ligands behave as full
agonists by inhibiting cAMP formation in the presence or
in the absence of constitutive CB2 activation. On the other
hand, MH and 27a show partial agonism for G-protein ac-
tivation and β-arrestin recruitment. Partial agonists are
very ductile pharmacological tools which can modulate
the activation state of a certain receptor in both ways.
Indeed, MH could either potentiate or attenuate the CB2-
mediated G-protein recruitment triggered by residual 2-
AG, depending on the concentration ratio between the
two ligands. This pharmacological feature might at least in
part explain the discrepancy between the different effects
reported for MH at CB2 receptors (agonist vs. inverse
agonist), due to the presence of high or low amounts of 2-
AG in the culture medium. We recently reported that fetal
bovine serum (FBS) contains ECs, and, depending on the
batch, the levels of 2-AG can even reach sub-micromolar
concentrations [46]. Culturing RAW264.7 cells with 2-AG
high-content sera led to significant formation of osteo-
clasts [46]. In this scenario, the partial agonists MH and
27a might exert their anti-osteoclastogenesis effects indir-
ectly by blocking 2-AG-induced CB2-mediated osteoclas-
togenesis. Our current results also suggest that alternative
signaling pathways than cAMP might be involved. In line
with this hypothesis, Schuehly et al. [1] reported the agon-
istic behavior of MH on CB2-mediated increase of intra-
cellular [Ca2+], while here, we report that MH triggers the
recruitment of β-arrestin, which might contribute to the
modulation of different downstream effectors. In addition,
we described that the 2-O-butyl honokiol derivative (34a)
acts as a ‘protean agonist’ as it could behave as an agonist
or inverse agonist, depending on the proportion of consti-
tutively activated CB2 receptors. On the contrary the CB2
inverse agonist AM630 switched from an inverse agonist
to an inactive ligand upon the removal of the constitutive
activity of the receptors in both [35S]GTPγS and cAMP as-
says (see Figure 8A and Additional file 1: Figure S1), thus
confirming that 34a is not simply behaving as an inverse
agonist. Noteworthy, upon i.p. application, MH treat-
ment significantly increased the brain levels of 2-AG in
a concentration-dependent manner without signifi-
cantly affecting AEA, AA, PGE2, and corticosterone
levels. These findings clearly suggest that the inhibition
of COX-2-mediated oxygenation as metabolic pathwayfor EC degradation in conditions of inflammation is a
relevant target for MH. Unfortunately, in vivo we and
others could not detect PGE2-GE, probably due to an
extensive hydrolysis to the related arachidonoyl deriva-
tive (PGE2), as previously shown [47,48]. Also, the effect
of SSIs may turn out to be different, dependent on
mouse strains. Recently, Hermanson et al. [21] reported
using a morpholino amide derivative of indomethacin,
LM-4131, a 150% increase of AEA levels and only minor
effects on 2-AG levels (~110%) in imprinting control re-
gion (ICR) mouse brain. In normal conditions, 2-AG
predominantly undergoes hydrolytic degradation
[49,50], but upon LPS-challenge, COX-2 levels signifi-
cantly rise in neurons [51] and astrocytes/microglial
cells [52], thus increasing the relevance of the oxygen-
ation pathway. In our setting we detected a significant
increase of 2-AG levels by 170% and 200% upon treat-
ment with 10 and 20 mg kg−1 of MH, respectively. AEA
levels were not significantly changed by MH treatment
despite a tendency to increase (120%) at the dose of 20
mg kg−1. In addition, MH treatment selectively modu-
lated the levels of 2-AG without affecting the levels of
AA, PGE2, the FAAH-substrates N-acetylethanola-
mines, and corticosterone. Therefore, SSI of COX-2 ac-
tivity appears to be a promising strategy to modulate EC
levels in the brain, especially under inflammatory condi-
tions. Prostamides and PG-GEs play an active role in
the inflammatory process both in vitro and in vivo by
acting through CB1/2 receptor-independent targets
[15,19,53]. In hippocampal neurons, COX-2 inhibition
rather than FAAH blockage led to a prolonged
depolarization-induced suppression of inhibition sug-
gesting a prominent role of 2-AG in the retrograde sig-
nal and COX-2-mediated oxygenation as relevant
mechanism of reducing 2-AG levels at the synaptic level
[54]. Straiker et al. [55] also reported the relevant role
of COX-2 activity in reducing EC-mediated retrograde
signaling. Recently it was shown that MH can weakly
potentiate GABA-induced chloride currents in Xenopus
oocytes by acting at the most common α1β2γ2 GABAA
receptor subtype [8]. In an animal model, repeated low
doses (0.5 mg kg−1 per os) of MH produced weak anxio-
lytic effects [56] similar to the SSI LM-4131 [21]. Thus,
MH could represent a prototype of multi-target compound
which can directly and indirectly potentiate the ECS. None-
theless, the pharmacokinetic profile of MH indicates a poor
oral bioavailability and extensive hepatic metabolism in rats
[57]. Our data show that upon i.p. injection, MH penetrates
the brain at concentrations which are in line with the ef-
fects on CB2 receptors and the SSI of COX-2 activity (ap-
proximately 200 and 300 nM for 10 and 20 mg kg−1,
respectively). Mice were sacrificed 7 h after the injection,
thus indicating that MH could reach and accumulate in the
brain without being significantly metabolized.
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administration [57], upon repeated doses, MH might ac-
cumulate and exert pharmacological effects in the brain.
This could also explain the beneficial effects reported for
long-term treatment with low doses of MH administered
per os (0.1 to 1 mg kg−1) in neurodegenerative animal
models [2,4,36]. CB2 receptors are almost absent in the
CNS under normal conditions, but upon inflammation,
they are significantly upregulated in microglial cells. Neu-
roinflammation is a hallmark of neurodegenerative dis-
eases which contributes to the onset and progression of
the disease [58,59] and several results support the positive
role of CB2 activation in neurodegenerative diseases in-
cluding the stimulation of β-amyloid removal by macro-
phages and down-regulation of TNF-α production
[60-62]. MH showed beneficial effects in Alzheimer’s dis-
ease (AD) models by reducing LPS-induced β-amyloid ac-
cumulation, pro-inflammatory cytokine production, and
memory impairment [2,4]. Since in addition to the direct
activation of CB2 receptors, MH also elevates 2-AG levels,
which is the main endogenous agonist for CB2, and it fur-
ther inhibits the formation of pro-inflammatory PG-EAs
and PG-GEs; synergistic effects for attenuating the inflam-
matory process are expected to represent one of the main
underlying mechanisms of the neuroprotective effects
exerted by MH. Interestingly, (R)-flurbiprofen is a COX-2
SSI with negligible effects on AA metabolism [14] which
showed COX-2-independent anti-inflammatory effects in
AD and experimental autoimmune encephalomyelitis
multiple sclerosis models [63-65]. Remarkably, in this
model, (R)-flurbiprofen induced a significant increase of
EC levels in the spinal cord and somatosensory cortex
while only mildly affecting PGs levels [65]. Therefore,
based on our data we suggest that the major mode of ac-
tion related to the pronounced neuroprotective effects of
MH may be related to its outstanding polypharmacology
in the ECS.
Conclusions
We show for the first time that MH penetrates the
blood-brain barrier and accumulates in the brain in
amounts that are consistent with the concentrations that
modulate the ECS in vitro. MH might serve as prototype
scaffold to develop compounds exhibiting a novel com-
bination of polypharmacology to modulate the ECS
through a concurrent activation of CB2 receptors and
the SSI of COX-2-mediated EC oxygenation. For MH,
the latter mechanism was shown here for the first time
both in vitro and in vivo. This polypharmacology might
achieve synergistic anti-inflammatory and protective ac-
tions in certain tissues, including the brain, by directly
and indirectly ( increasing 2-AG levels) activating CB2
receptors, avoiding the typical gastrointestinal and car-
diovascular side effects of NSAIDs. Moreover, these twomechanisms of action might be more relevant in neu-
roinflammatory diseases where both COX-2 and CB2 re-
ceptors are overexpressed in the brain, thus providing a
rationale for the diverse neuroprotective effects reported
for MH in animal models.
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